<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-37202-2S4</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Molecular insights in HIV-specific CD8+ T cell dysfunction: cause and consequence</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">ART potently suppresses HIV replication, however the virus is not eradicated and persists in latent reservoirs. Consequently, viral replication rebounds after ART interruption in the majority of patients.
To obtain a functional cure, it is necessary to reduce the viral reservoir and gain immune control. CD8+ T cells are able to control
HIV infection in elite controllers, whereas these cells are exhausted and dysfunctional in progressing patients and their function is not restored during ART. Additional interventions like therapeutic vaccination or immune therapeutics, may improve HIV-specific
responses thereby increasing the chance to achieve a functional cure after ART interruption.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Although ART is very successful, it cannot eliminate the viral reservoir and lifelong treatment of HIV infected individuals is fundamental. Curing HIV infection will require boosting of the immune system to control HIV upon treatment interruption. CD8+ T cell responses have been demonstrated to play a crucial role in natural control of HIV infection, however these responses fail during progressive disease. To gain more insight into CD8+ T cell
dysfunction in HIV infection, we will perform an in depth molecular analysis of HIV-specific CD8+ T cell responses in progressive infection and during immune control. This research will reveal functional pathways associated with CD8+ T cells functionality at an individual level, presenting opportunities for new therapeutic approaches and personalized medicine to gain HIV immune control.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">Scientific community involved in HIV cure and immunology research. Outcomes of the project may eventually affect the whole HIVinfected population.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">To identify molecular mechanisms involved in CD8+ T cell dysfunction, we will analyze and compare the gene expression profile and function of HIV-specific CD8+ T cells from EC and CHI. In addition, a similar analysis of CMV-specific CD8+ T cells (same patient) will be analyzed to determine whether molecular pathwaysassociated with CD8+ T cell dysfunction is  virus-specific or related to the general immune activation and perturbed immune function. This research will provide molecular insights in CD8+ T celldysfunction in HIV infection and may identify new  targets for immune therapeutic approaches.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2018-11-15" type="2"></activity-date>
  <activity-date iso-date="2020-02-15" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C52" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2018-11-15"></period-start>
   <period-end iso-date="2020-02-15"></period-end>
   <value currency="EUR" value-date="2018-11-15">227800</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">75000</value>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">67500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-08-25"></transaction-date>
   <value currency="EUR" value-date="2020-08-25">7500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-08-26"></transaction-date>
   <value currency="EUR" value-date="2020-08-26">7500</value>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Experimentele immunologie</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-34501-2S4" type="1"></related-activity>
 </iati-activity>
</iati-activities>
